Literature DB >> 26573338

Compared in vivo toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles.

Letícia Aragao-Santiago1,2, Hervé Hillaireau1,2, Nadège Grabowski1,2, Simona Mura1,2, Thais L Nascimento1,2, Sandrine Dufort3,4, Jean-Luc Coll3,4, Nicolas Tsapis1,2, Elias Fattal1,2.   

Abstract

To design nanoparticle (NP)-based drug delivery systems for pulmonary administration, biodegradable materials are considered safe, but their potential toxicity is poorly explored. We here explore the lung toxicity in mice of biodegradable nanoparticles (NPs) and compare it to the toxicity of non-biodegradable ones. NP formulations of poly(d,l-lactide-co-glycolide) (PLGA) coated with chitosan (CS), poloxamer 188 (PF68) or poly(vinyl alcohol) (PVA), which renders 200 nm NPs of positive, negative or neutral surface charge respectively, were analyzed for their biodistribution by in vivo fluorescence imaging and their inflammatory potential after single lung nebulization in mice. After exposure, analysis of bronchoalveolar lavage (BAL) cell population, protein secretion and cytokine release as well as lung histology were carried out. The inflammatory response was compared to the one induced by non-biodegradable counterparts, namely, TiO2 of rutile and anatase crystal form and polystyrene (PS). PLGA NPs were mostly present in mice lungs, with little passage to other organs. An increase in neutrophil recruitment was observed in mice exposed to PS NPs 24 h after nebulization, which declined at 48 h. This result was supported by an increase in interleukin (IL)-6 and tumor necrosis factor α (TNFα) in BAL supernatant at 24 h. TiO2 anatase NPs were still present in lung cells 48 h after nebulization and induced the expression of pro-inflammatory cytokines and the recruitment of polymorphonuclear cells to BAL. In contrast, regardless of their surface charge, PLGA NPs did not induce significant changes in the inflammation markers analyzed. In conclusion, these results point out to a safe use of PLGA NPs regardless of their surface coating compared to non-biodegradable ones.

Entities:  

Keywords:  Biodegradable; inflammation; lung; nanoparticle

Mesh:

Substances:

Year:  2015        PMID: 26573338     DOI: 10.3109/17435390.2015.1054908

Source DB:  PubMed          Journal:  Nanotoxicology        ISSN: 1743-5390            Impact factor:   5.913


  9 in total

1.  Chitinase Induction Prior to Caspofungin Treatment of Experimental Invasive Aspergillosis in Neutropenic Rats Does Not Enhance Survival.

Authors:  Jeannine M Refos; Alieke G Vonk; Marian T Ten Kate; Henri A Verbrugh; Irma A J M Bakker-Woudenberg; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.

Authors:  Joana Costa-Gouveia; Elisabetta Pancani; Samuel Jouny; Arnaud Machelart; Vincent Delorme; Giuseppina Salzano; Raffaella Iantomasi; Catherine Piveteau; Christophe J Queval; Ok-Ryul Song; Marion Flipo; Benoit Deprez; Jean-Paul Saint-André; José Hureaux; Laleh Majlessi; Nicolas Willand; Alain Baulard; Priscille Brodin; Ruxandra Gref
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

3.  Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity.

Authors:  Aws Alshamsan; Ziyad Binkhathlan; Mohd Abul Kalam; Wajhul Qamar; Hala Kfouri; Mohammed Alghonaim; Afsaneh Lavasanifar
Journal:  Sci Rep       Date:  2020-04-21       Impact factor: 4.379

Review 4.  Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far.

Authors:  Sandra Jesus; Mélanie Schmutz; Claudia Som; Gerrit Borchard; Peter Wick; Olga Borges
Journal:  Front Bioeng Biotechnol       Date:  2019-10-23

5.  Modulating lung immune cells by pulmonary delivery of antigen-specific nanoparticles to treat autoimmune disease.

Authors:  Eiji Saito; Stephen J Gurczynski; Kevin R Kramer; Carol A Wilke; Stephen D Miller; Bethany B Moore; Lonnie D Shea
Journal:  Sci Adv       Date:  2020-10-16       Impact factor: 14.136

Review 6.  Cationic Nanomaterials for Autoimmune Diseases Therapy.

Authors:  Baozhao Xie; Keqian Du; Fujian Huang; Zhiming Lin; Linping Wu
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

7.  Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles.

Authors:  Andrea Fodor-Kardos; Ádám Ferenc Kiss; Katalin Monostory; Tivadar Feczkó
Journal:  RSC Adv       Date:  2020-04-22       Impact factor: 4.036

8.  In vivo Studies on Pharmacokinetics, Toxicity and Immunogenicity of Polyelectrolyte Nanocapsules Functionalized with Two Different Polymers: Poly-L-Glutamic Acid or PEG.

Authors:  Alicja Karabasz; Krzysztof Szczepanowicz; Agnieszka Cierniak; Renata Mezyk-Kopec; Grzegorz Dyduch; Marta Szczęch; Joanna Bereta; Monika Bzowska
Journal:  Int J Nanomedicine       Date:  2019-12-05

Review 9.  An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.

Authors:  Munawar A Mohammed; Jaweria T M Syeda; Kishor M Wasan; Ellen K Wasan
Journal:  Pharmaceutics       Date:  2017-11-20       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.